EA038188B1 - Способ лечения gd2-положительного рака - Google Patents

Способ лечения gd2-положительного рака Download PDF

Info

Publication number
EA038188B1
EA038188B1 EA201500019A EA201500019A EA038188B1 EA 038188 B1 EA038188 B1 EA 038188B1 EA 201500019 A EA201500019 A EA 201500019A EA 201500019 A EA201500019 A EA 201500019A EA 038188 B1 EA038188 B1 EA 038188B1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
dose
administered
morphine
day
Prior art date
Application number
EA201500019A
Other languages
English (en)
Russian (ru)
Other versions
EA201500019A1 (ru
Inventor
Ханс Лойбнер
Манфред Шустер
Эвелин Янцек-Хавлат
Сюзанн Видеркум
Бернхард Пебаль
Штефан Штраннер
Оливер Мучлехнер
Франц Гройсс
Рут Ладенштайн
Хольгер Лоде
Original Assignee
Апейрон Биолоджикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апейрон Биолоджикс Аг filed Critical Апейрон Биолоджикс Аг
Publication of EA201500019A1 publication Critical patent/EA201500019A1/ru
Publication of EA038188B1 publication Critical patent/EA038188B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201500019A 2012-06-18 2012-07-31 Способ лечения gd2-положительного рака EA038188B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/061618 WO2013189516A1 (en) 2012-06-18 2012-06-18 Method for treating a gd2 positive cancer
PCT/EP2012/064970 WO2013189554A1 (en) 2012-06-18 2012-07-31 Method for treating a gd2 positive cancer

Publications (2)

Publication Number Publication Date
EA201500019A1 EA201500019A1 (ru) 2015-05-29
EA038188B1 true EA038188B1 (ru) 2021-07-21

Family

ID=46317406

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500019A EA038188B1 (ru) 2012-06-18 2012-07-31 Способ лечения gd2-положительного рака

Country Status (15)

Country Link
US (4) US10294305B2 (enExample)
JP (1) JP6283665B2 (enExample)
KR (1) KR101927118B1 (enExample)
CN (1) CN104487088A (enExample)
AP (1) AP2014008129A0 (enExample)
AU (1) AU2012383254B2 (enExample)
BR (1) BR112014031806A8 (enExample)
CA (1) CA2876529C (enExample)
EA (1) EA038188B1 (enExample)
HK (1) HK1203375A1 (enExample)
IL (1) IL235696A0 (enExample)
MX (1) MX377157B (enExample)
SG (2) SG11201408487WA (enExample)
WO (2) WO2013189516A1 (enExample)
ZA (1) ZA201407961B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EP4218811A1 (en) 2012-06-18 2023-08-02 Apeiron Biologics AG Method for treating a gd2 positive cancer
ES2768649T3 (es) 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
DK3154583T3 (da) * 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CA3076482A1 (en) * 2017-09-21 2019-03-28 Umc Utrecht Holding B.V. Anti-gd2 antibody for the treatment of neuroblastoma
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
WO2020165402A1 (en) 2019-02-14 2020-08-20 Westfälische Wilhelms-Universität Münster Gd2-upregulation by ezh2 inhibition in cancer therapy
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
ES3031393T3 (en) * 2019-08-01 2025-07-08 Univ Mie Gd2 binding molecule
EP4093429A4 (en) * 2019-11-26 2024-05-22 University of Utah Research Foundation COMPOSITIONS AND METHODS FOR REGULATION OF HLA CLASS I ON TUMOR CELLS
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023532753A (ja) 2020-07-06 2023-07-31 イーユーエスエー ファーマ (ユーケー) リミテッド Gd2陽性がんを治療するための方法
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
JP2024524527A (ja) * 2021-07-05 2024-07-05 トリオン リサーチ ゲーエムベーハー がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体
EP4194471A1 (en) * 2021-12-10 2023-06-14 Y-Mabs Therapeutics, Inc. Anti-gd2 administration regimen
GB202307103D0 (en) 2023-05-12 2023-06-28 Prinses Maxima Centrum Voor Kinderoncologie B V Method for detecting a GD2 positive cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160119A2 (en) * 2010-06-19 2011-12-22 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
CN101292036B (zh) 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
TWI466684B (zh) 2008-06-30 2015-01-01 Morphotek Inc 抗gd2抗體及其相關方法及用途
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EP4218811A1 (en) 2012-06-18 2023-08-02 Apeiron Biologics AG Method for treating a gd2 positive cancer
US9840566B2 (en) * 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
ES2768649T3 (es) 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160119A2 (en) * 2010-06-19 2011-12-22 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ALICE L. YU, ANDREW L. GILMAN, M. FEVZI OZKAYNAK, WENDY B. LONDON, SUSAN G. KREISSMAN, HELEN X. CHEN, MALCOLM SMITH, BARRY ANDERSO: "Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma", NEW ENGLAND JOURNAL OF MEDICINE, NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, no. 14, 30 September 2010 (2010-09-30), pages 1324 - 1334, XP055045834, ISSN: 00284793, DOI: 10.1056/NEJMoa0911123 *
BATOVA A, ET AL.: "THE CH14.18-GM-CSF FUSION PROTEIN IS EFFECTIVE AT MEDIATING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY AND COMPLEMENT-DEPENDENT CYTOTOXICITY IN VITRO", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 05, no. 12, 1 December 1999 (1999-12-01), US, pages 4259 - 4263, XP001042232, ISSN: 1078-0432 *
CHAMES PATRICK , BATY DANIEL: "Bispecific antibodies for cancer therapy. The light at the end of the tunnel?", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 6, 1 November 2009 (2009-11-01), US, pages 539 - 547, XP002688758, ISSN: 1942-0862, DOI: 10.4161/mabs.1.6.10015 *
HANDGRETINGER R; BAADER P; DOPFER R; KLINGEBIEL T; REULAND P; TREUNER J; REISFELD R A; NIETHAMMER D: "A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 35, no. 3, 1 January 1992 (1992-01-01), Berlin/Heidelberg, pages 199 - 204, XP009165370, ISSN: 0340-7004, DOI: 10.1007/BF01756188 *
JAMI D. FROST, JACQUELYN A. HANK, GREGORY H. REAMAN, SHARON FRIERDICH, ROBERT C. SEEGER, JACEK GAN, PETER M. ANDERSON, LAWRENCE J.: "A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma", CANCER, �JOHN WILEY & SONS| :, vol. 80, no. 2, 15 July 1997 (1997-07-15), pages 317 - 333, XP055045923, ISSN: 0008543X, DOI: 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W *
Lode, H. and Dobke, J.: "A Phase I/II Dose Schedule Finding Study of ch14.18/CH0 Continuous Infusion Combined with Subcutaneous Aldesleukin (=Proleukin) (IL-2) in Patients with Primary Refractory or Relapsed Neuroblastoma. A SIOPEN Study", 13 June 2012 (2012-06-13), pages 1-3, XP002688973, Retrieved from the Internet: URL:http://www.kinderkrebsinfo.de/health_professionals/clinical_trials/phase_i_ii_trials_in_the_gpoh/longterminfusion_study_lti_ch1418/index_eng.html [retrieved on 2012-12-10], the whole document *
MUELLER B M, ET AL.: "ENHANCEMENT OF ANTIBODY-DEPENDENT CYTOTOXICITY WITH A CHIMERIC ANTI-GD2 ANTIBODY", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 144, no. 04, 15 February 1990 (1990-02-15), US, pages 1382 - 1386, XP002934990, ISSN: 0022-1767 *
MURRAY J L; CUNNINGHAM J E; BREWER H; MUJOO K; ZUKIWSKI A A; PODOLOFF D A; KASI L P; BHADKAMKAR V; FRITSCHE H A; BENJAMIN R S; ET : "Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.", JOURNAL OF CLINICAL ONCOLOGY, vol. 12, no. 1, 1 January 1994 (1994-01-01), pages 184 - 193, XP009165391, ISSN: 0732-183X *
NAVID FARIBA ET AL: "Anti-GD2 antibody therapy for GD2-expressing tumors.", CURRENT CANCER DRUG TARGETSNETHERLANDSJUL 2013, BENTHAM SCIENCE PUBLISHERS LTD., NL, vol. 10, no. 2, 1 March 2010 (2010-03-01), NL, pages 200 - 209, XP002688757, ISSN: 1873-5576, DOI: 10.2174/156800910791054167 *
R. HANDGRETINGER, K. ANDERSON, P. LANG, R. DOPFER, T. KLINGEBIEL, M. SCHRAPPE, P. REULAND, S.D. GILLIES, R.A. REISFELD, D. NIETHAM: "A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma", EUROPEAN JOURNAL OF CANCER, PERGAMON, vol. 31, no. 2, 1 January 1995 (1995-01-01), pages 261 - 267, XP055045925, ISSN: 09598049, DOI: 10.1016/0959-8049(94)00413-Y *
SALEH M N, KHAZAELI M B, WHEELER R H, DROPCHO E, LIU T, URIST M, MILLER D M, LAWSON S, DIXON P, RUSSELL C H, LOBUGLIO A F: "PHASE I TRIAL OF THE MURINE MONOCLONAL ANTI-G-D-2 ANTIBODY 14G2A IN METASTATIC MELANOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 52, no. 16, 15 August 1992 (1992-08-15), pages 4342 - 4347, XP002688756, ISSN: 0008-5472 *
YU A L; UTTENREUTHER-FISCHER M M; HUANG C S; TSUI C C; GILLIES S D; REISFELD R A; KUNG F H: "Phase I trial of a human-Mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 6, 1 June 1998 (1998-06-01), pages 2169 - 2180, XP008120914, ISSN: 0732-183X *

Also Published As

Publication number Publication date
CN104487088A (zh) 2015-04-01
AU2012383254A1 (en) 2014-11-20
KR20150030650A (ko) 2015-03-20
AP2014008129A0 (en) 2014-12-31
US20180134801A1 (en) 2018-05-17
WO2013189516A1 (en) 2013-12-27
BR112014031806A8 (pt) 2018-01-16
US20200055953A1 (en) 2020-02-20
BR112014031806A2 (pt) 2017-08-29
JP2015521607A (ja) 2015-07-30
JP6283665B2 (ja) 2018-02-21
CA2876529A1 (en) 2013-12-27
ZA201407961B (en) 2015-10-28
AU2012383254B2 (en) 2017-12-14
US11447565B2 (en) 2022-09-20
KR101927118B1 (ko) 2019-03-12
WO2013189554A1 (en) 2013-12-27
EA201500019A1 (ru) 2015-05-29
SG11201408487WA (en) 2015-02-27
HK1203375A1 (en) 2015-10-30
US20230340148A1 (en) 2023-10-26
CA2876529C (en) 2023-09-26
US10294305B2 (en) 2019-05-21
IL235696A0 (en) 2015-01-29
SG10201610532QA (en) 2017-02-27
US20140170155A1 (en) 2014-06-19
MX377157B (es) 2025-03-07
MX2014013858A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
EA038188B1 (ru) Способ лечения gd2-положительного рака
EP2331579B1 (en) Monoclonal antibodies
ES3041987T3 (en) Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
TWI324161B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
US20230034186A1 (en) Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP6533534B2 (ja) 膠芽腫の治療に使用するための組成物及びその使用
AU2020203346A1 (en) Preparations And Methods For Treating A GD2 Positive Cancer
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
US20210000949A1 (en) Methods for treating or preventing asthma by administering an il-33 antagonist
US11591395B2 (en) Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
CN106519036A (zh) 抗cd47和egfr的双功能蛋白及其制备方法与应用
WO2018183366A1 (en) Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CA3122333A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
EP4023679A1 (en) Fusion protein targeting pd-l1 and tgf-beta and use thereof
KR20220002900A (ko) 항-psma/cd3 항체로 신장암을 치료하는 방법
JP2022532928A (ja) 全身性硬化症を治療するための方法
JP2024529451A (ja) がんを治療するための方法及び組成物
US20230035183A1 (en) Antibodies for the treatment of chronic graft versus host disease
CN118126181B (zh) 人和猴交叉种属抗ccr8膜蛋白抗体
Elkordy¹ et al. Application of approved and marketed products of
WO2025108438A1 (zh) 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
JP2024527049A (ja) がんを治療するための方法及び組成物
CN117940452A (zh) 用于治疗癌症的方法和组合物